FLJ34931_BC027072 Inhibitors
FLJ34931_BC027072 inhibitors are a class of chemical compounds that have gained significant attention in the field of molecular biology and pharmacology due to their role in modulating specific cellular processes. These inhibitors are designed to target and interact with the FLJ34931 and BC027072 proteins, which are encoded by the respective FLJ34931 and BC027072 genes. FLJ34931 is also known as C8orf4 (Chromosome 8 Open Reading Frame 4), and BC027072 is an alias for a long non-coding RNA (lncRNA) molecule. While the exact biological functions of these proteins and RNA molecules are not yet fully understood, research suggests that they may play critical roles in various cellular pathways, including signal transduction, gene regulation, and cellular differentiation.
The development and study of FLJ34931_BC027072 inhibitors primarily focus on elucidating the precise mechanisms by which these compounds interact with their target molecules. Researchers aim to understand how these inhibitors affect the activity of FLJ34931 and BC027072, as well as their downstream cellular effects. This research is crucial for advancing our knowledge of cell biology and may have implications for the development of novel tools for molecular research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor that interferes with the growth of cancer cells by blocking signal pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL, c-KIT, and PDGFR, blocking the growth of cancer cells by inhibiting tyrosine kinase. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets BCR-ABL and SRC family kinases, inhibiting tyrosine kinase activity, affecting cell growth. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor inhibiting degradation of pro-apoptotic factors, inducing cancer cell death. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor blocking activation of the MAPK pathway, affecting cell proliferation and apoptosis. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that arrests cell cycle progression by inhibiting retinoblastoma protein phosphorylation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF kinase inhibitor stopping signal transduction in the MAPK pathway, inhibiting tumor cell growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor affecting cell proliferation and angiogenesis by inhibiting various receptors. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual tyrosine kinase inhibitor affecting EGFR and HER2/neu receptors, inhibiting cell proliferation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor blocking cell proliferation and angiogenesis, affecting various cellular functions. | ||||||